Direkt zum Inhalt
Merck

Exploring the target scope of KEAP1 E3 ligase-based PROTACs.

Cell chemical biology (2022-09-08)
Guangyan Du, Jie Jiang, Nathaniel J Henning, Nozhat Safaee, Eriko Koide, Radosław P Nowak, Katherine A Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A Eleuteri, Zhixiang He, Zhengnian Li, Hubert T Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S Fischer, Nathanael S Gray
ZUSAMMENFASSUNG

Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into the proximity of proteins of interest, inducing ubiquitination-dependent degradation. A major bottleneck in the TPD field is the lack of accessible E3 ligase ligands for developing degraders. To expand the E3 ligase toolbox, we sought to convert the Kelch-like ECH-associated protein 1 (KEAP1) inhibitor KI696 into a recruitment handle for several targets. While we were able to generate KEAP1-recruiting degraders of BET family and murine focal adhesion kinase (FAK), we discovered that the target scope of KEAP1 was narrow, as targets easily degraded using a cereblon (CRBN)-recruiting degrader were refractory to KEAP1-mediated degradation. Linking the KEAP1-binding ligand to a CRBN-binding ligand resulted in a molecule that induced degradation of KEAP1 but not CRBN. In sum, we characterize tool compounds to explore KEAP1-mediated ubiquitination and delineate the challenges of exploiting new E3 ligases for generating bivalent degraders.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Roche
cOmplete Mini Proteasehemmer-Cocktail, Tablets provided in a glass vial
Sigma-Aldrich
Lenalidomide, ≥95%